[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"all-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:all-adult":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100535371","phase-2-rdc-blinatumomab-versus-hypercvad-for-ph-negative-b-all-100535371",false,"NCT06250959","RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.","Comparing the Efficacy and Safety of Reduced-dose Chemotherapy Followed by Blinatumomab Versus hyperCVAD as Induction Therapy for Newly Diagnosed Ph-negative B-ALL: a Multicenter, Radomized, Phase 2 Study","BEAT-ALL-2024","Inclusion Criteria:\n\n* Age 15-65\n* Ph-(BCR-ABL1 negative)B-ALL was diagnosed according to WHO diagnostic criteria\n* Newly diagnosed patients without prior induction therapy (except hydroxyurea and glucocorticoids ≦5 days\n* ECOG score 0-3\n* Liver function: total bilirubin ≦ 3 times the upper limit of normal; Alanine ·aminotransferase ≦ 3 times upper limit of normal motion; Aspartate aminotransferase ≦ 3 times upper limit of normal motion; (except considering leukemia infiltration)\n* Renal function: endogenous creatinine clearance ≧30ml\u002Fmin\n* Patients must be able to understand and willing to participate in the study and must sign the informed consent form.\n\nExclusion Criteria:\n\n* Ph+ (BCR-ABL1 positive) ALL\n* T cells ALL\n* Mature B-cell leukemia\u002Flymphoma, B-cell lymphoma, with extramedullary disease\n* Acute mixed-cell leukemia\n* Central nervous system leukemia\n* HIV infection\n* HBV-DNA or HCV-RNA positive\n* Patients with grade 2 or higher heart failure and other patients deemed inappropriate for inclusion by the investigator\n* Pregnant or breastfeeding patients\n* The study patient was refused enrollment","ALL","15 Years","65 Years",{"count":21,"type":22},124,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.",[28,29],"ALL, Adult","Philadelphia-Negative ALL","RECRUITING","2024-04-03",{"date":33,"type":34},"2024-04-04","ACTUAL",{"date":36,"type":34},"2024-02-05",{"date":38,"type":22},"2026-12-31",{"name":40,"class":41},"Chen Suning","OTHER"]